These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32667786)

  • 1. Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads.
    Lerchen HG; Stelte-Ludwig B; Sommer A; Berndt S; Rebstock AS; Johannes S; Mahlert C; Greven S; Dietz L; Jörißen H
    Bioconjug Chem; 2020 Aug; 31(8):1893-1898. PubMed ID: 32667786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.
    Lerchen HG; Stelte-Ludwig B; Berndt S; Sommer A; Dietz L; Rebstock AS; Johannes S; Marx L; Jörißen H; Mahlert C; Greven S
    Chemistry; 2019 Jun; 25(35):8208-8213. PubMed ID: 30869180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
    Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
    Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
    Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
    Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment.
    Edupuganti VVSR; Tyndall JDATDA; Gamble AB
    Recent Pat Anticancer Drug Discov; 2021; 16(4):479-497. PubMed ID: 33966624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.
    Sommer A; Berndt S; Lerchen HG; Forveille S; Sauvat A; Mumberg D; Kroemer G; Kepp O
    Oncoimmunology; 2022; 11(1):2037216. PubMed ID: 35154909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
    Kumar A; Mao S; Dimasi N; Gao C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
    Rebstock AS; Wiedmann M; Stelte-Ludwig B; Wong H; Johnson AJ; Izumi R; Hamdy A; Lerchen HG
    Front Pharmacol; 2024; 15():1358393. PubMed ID: 38495100
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
    Singh SK; Luisi DL; Pak RH
    Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates.
    Walker JA; Sorkin MR; Ledesma F; Kabaria SR; Barfield RM; Rabuka D; Alabi CA
    Bioconjug Chem; 2019 Nov; 30(11):2982-2988. PubMed ID: 31671265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.